Pivotal Trial Results of the iLet® Bionic Pancreas To Be Presented at ATTD
25 avr. 2022 05h00 HE
|
Beta Bionics, Inc.
Dr. Steven J. Russell will present the results from the multi-center randomized Insulin-Only Bionic Pancreas Pivotal Trial at the International Conference on Advanced Technologies & Treatments for...
Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board
21 mars 2022 09h37 HE
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, March 21, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the...
Beta Bionics Announces Executive Leadership and Board Transitions in Preparation for Commercialization of the iLet® Bionic Pancreas System
02 mars 2022 16h15 HE
|
Beta Bionics, Inc.
Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Dr. Ed Damiano, President & CEO of Beta...
vTv Therapeutics Shares Updated Corporate Presentation
13 janv. 2022 08h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Jan. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company committed to improving the quality of life for people with...
vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations
06 déc. 2021 17h19 HE
|
vTv Therapeutics Inc.
-Workforce reduction of 65% -Prioritization of lead program TTP399, a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes patients HIGH POINT, N.C.,...
vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update
09 nov. 2021 08h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2021, and provided an update on the...
vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
12 oct. 2021 07h30 HE
|
vTv Therapeutics Inc.
Study achieved primary endpoint of non-inferiority on measurement of key blood ketone levels Patients taking TTP399 reported no events of hypoglycemia, while four events of hypoglycemia were reported...
vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes
23 févr. 2021 10h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Feb. 23, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
Déclaration de Dave Prowten, président et chef de la direction de FRDJ Canada
12 août 2019 11h15 HE
|
Fondation de la recherche sur le diabète juvénile
TORONTO, 12 août 2019 (GLOBE NEWSWIRE) -- FRDJ suit de très près les développements en ce qui a trait à la récente annonce du Safe Importation Action Plan du Département de la Santé et des...
Statement by Dave Prowten, President and CEO JDRF Canada
12 août 2019 11h15 HE
|
Juvenile Diabetes Research Foundation Canada
TORONTO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- JDRF has been closely monitoring developments rising from the recent announcement of a “Safe Importation Action Plan” by the United States Department of...